Novo Nordisk wins Awiqli approval. Novo Nordisk stock is 0.43 percent above Xetra close

Published on 10/26/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Awiqli won FDA approval for children aged 10 and older. Novo Nordisk stock costs EUR 35.03 on October 26, 2026, 0.43 percent above Xetra close.

Pipeline and reporting milestones

Awiqli received FDA approval for children aged 10 and older on October 26, 2026.
Adjusted second-quarter sales reached DKK 78,488 million, up 7 percent at constant exchange rates.
Novo Nordisk stock trades at EUR 35.03 at 10:31 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.43 percent above the Xetra close of October 23, 2026.
Novo Nordisk is scheduled to release third-quarter results on November 3, 2026.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk (DK0062498333) was trading at EUR 35.03 at Lang & Schwarz on October 26, 2026 at 10:31 a.m. CEST, plus 0.43 percent versus the Xetra close of October 23, 2026 (EUR 34.88). Simply Wall St reported that the US Food and Drug Administration approved Awiqli for children aged 10 and older with type 2 diabetes. The decision adds a pediatric use to Novo Nordisk's once-weekly insulin portfolio.

Awiqli adds a pediatric option

The approval gives Novo Nordisk another product milestone as investors assess the company's ability to broaden its diabetes franchise beyond obesity medicines. The decision concerns insulin icodec and reduces basal insulin injections from seven per week to one, according to the report from Simply Wall St.

What does the outlook imply?

The latest reported quarter showed adjusted sales of DKK 78,488 million, up 7 percent at constant exchange rates, while adjusted operating profit rose 11 percent to DKK 33,389 million in the second quarter of 2026. Globenewswire said Novo Nordisk raised its 2026 adjusted sales and adjusted operating profit outlook to a decline of 0 percent to 6 percent at constant exchange rates, compared with a decline of 4 percent to 12 percent previously.

Three dated milestones

The chronology shows how the investment case has shifted. On August 4, 2026, Novo Nordisk reported DKK 78,488 million in adjusted second-quarter sales and 7 percent growth at constant exchange rates, according to Globenewswire. On September 29, 2026, it agreed a licensing deal worth up to USD 2.6 billion for an oral GLP-1 and GIP treatment, as reported by Simply Wall St. On October 26, 2026, the FDA approval of Awiqli for children aged 10 and older supplied the latest product event.

Upcoming reporting date

The next substantiated date is November 3, 2026, when Novo Nordisk is scheduled to release third-quarter results, according to MarketScreener. That report will test whether the improved first-half sales trend can offset the full-year outlook for a 0 percent to 6 percent decline at constant exchange rates.

Stock holds above the Xetra close

The small premium to the previous Xetra session leaves the stock's next signal tied more closely to the upcoming results than to the day's price move. Novo Nordisk's B shares are listed on Nasdaq Copenhagen, while its American depositary receipts trade on the New York Stock Exchange, according to the company release.

Novo Nordisk was trading at EUR 35.03 at Lang & Schwarz on October 26, 2026 at 10:31 a.m. CEST, plus 0.43 percent versus the Xetra close of October 23, 2026 at EUR 34.88. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.